›› 2010, Vol. 30 ›› Issue (9): 1072-.doi: 10.3969/j.issn.1674-8115.2010.09.013

• Monographic report (Medical imaging and nuclear medicine) • Previous Articles     Next Articles

Progress of application of 18F-FDG PET and PET/CT in assessment of response of tumor to neoadjuvant chemotherapy

ZHANG Min, reviewer;LI Biao, reviser   

  1. Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
  • Online:2010-09-25 Published:2010-09-27
  • Supported by:

    Shanghai Leading Academic Discipline Project, S30203

Abstract:

Neoadjuvant chemotherapy is increasingly widely used in the treatment of cancer, and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and PET/CT play a role in the early assessment of response to neoadjuvant chemotherapy, including tumor restaging, drug selection and prognosis prediction, which facilitate the design of therapeutic regimen and reduction of ineffective therapy.The progress of application of 18F-FDG PET and PET/CT in the assessment of response of tumor to neoadjuvant chemotherapy is reviewed in this paper.

Key words: positron emission tomography, 18F-fluorodeoxyglucose, tumor, neoadjuvant chemotherapy